Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

767
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
767
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

44
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
44
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

53
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
53
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

304
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
304
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

414
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
414

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China.

Neurology·2026
Same author

Endothelial FAM171A2 is required for maintaining autophagy flux and blood-brain barrier integrity.

Science bulletin·2026
Same author

Bridging the dimensional gap from planar spatial transcriptomics to 3D cell atlases.

Nature methods·2025
Same author

FAM171A2 in Parkinson's disease: mechanistic insights for a future therapeutic target.

Expert opinion on therapeutic targets·2025
Same author

Clinical Utility of Plasma GFAP and NEFL as Biomarkers for Dementia in the Community.

Journal of neurochemistry·2025
Same author

MS4A6A/Ms4a6d deficiency disrupts neuroprotective microglia functions and promotes inflammation in Alzheimer's disease model.

Molecular neurodegeneration·2025

Related Experiment Video

Updated: Sep 27, 2025

Perspectives on Neuroscience
26:41

Perspectives on Neuroscience

Published on: July 31, 2007

5.1K

Tauopathies: new perspectives and challenges.

Yi Zhang1, Kai-Min Wu1, Liu Yang1

  • 1Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, 12th Wulumuqi Zhong Road, Shanghai, 200040, China.

Molecular Neurodegeneration
|April 8, 2022
PubMed
Summary
This summary is machine-generated.

Tauopathies, neurodegenerative diseases marked by tau protein, present diverse symptoms. Research synthesizes clinical, pathological, and genetic data to advance tau-directed therapies for these untreatable conditions.

Keywords:
BiomarkersGeneticsNeurodegenerationTauopathiesTherapeutics

More Related Videos

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
12:47

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins

Published on: December 27, 2016

19.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Related Experiment Videos

Last Updated: Sep 27, 2025

Perspectives on Neuroscience
26:41

Perspectives on Neuroscience

Published on: July 31, 2007

5.1K
Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
12:47

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins

Published on: December 27, 2016

19.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Area of Science:

  • Neuroscience
  • Neuropathology
  • Genetics

Background:

  • Tauopathies are neurodegenerative disorders defined by tau-positive inclusions in neurons and glia.
  • These conditions manifest with varied clinical symptoms, including cognitive, behavioral, movement, and language deficits.

Purpose of the Study:

  • To synthesize current knowledge on tauopathies from clinical, pathological, genetic, and experimental studies.
  • To develop a unified understanding of tauopathies to accelerate therapeutic development.

Main Methods:

  • Review and synthesis of existing research on tauopathies.
  • Analysis of clinical presentations, pathological classifications (3R, 4R tau isoforms), and genetic links.
  • Evaluation of imaging, cerebrospinal fluid (CSF), and blood-based biomarkers for diagnostic potential.

Main Results:

  • Tauopathies exhibit diverse clinical phenotypes and pathological classifications based on tau isoforms.
  • Biomarkers (imaging, CSF, blood) show promise for routine diagnostics.
  • Strong links between tau protein abnormalities and tauopathies fuel interest in targeted therapeutics.

Conclusions:

  • Tauopathies remain untreatable, necessitating continued research.
  • Efforts focus on characterizing clinical/pathological features, identifying biomarkers, and understanding pathogenesis for early diagnosis and disease-modifying therapies.